2024 |
Protocol for generation and engineering of thyroid cell lineages using CRISPR-Cas9 editing to recapitulate thyroid cancer histotype progression |
Articolo in rivista |
Vai |
2023 |
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells |
Articolo in rivista |
Vai |
2023 |
EBF1, MYO6 and CALR expression levels predict therapeutic response in diffuse large B-cell lymphomas |
Articolo in rivista |
Vai |
2023 |
Recapitulating thyroid cancer histotypes through engineering embryonic stem cells |
Articolo in rivista |
Vai |
2022 |
Cancer cell targeting by CAR-T cells: A matter of stemness |
Review essay (rassegna critica) |
Vai |
2022 |
Targeting of the Peritumoral Adipose Tissue Microenvironment as an Innovative Antitumor Therapeutic Strategy |
Review essay (rassegna critica) |
Vai |
2022 |
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers |
Articolo in rivista |
Vai |
2022 |
Targeting epigenetic alterations in cancer stem cells |
Review essay (rassegna critica) |
Vai |
2022 |
Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy |
Articolo in rivista |
Vai |
2022 |
Destroying the Shield of Cancer Stem Cells: Natural Compounds as Promising Players in Cancer Therapy |
Review essay (rassegna critica) |
Vai |
2022 |
Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers |
Nota o commento |
Vai |
2022 |
Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells |
Articolo in rivista |
Vai |
2021 |
Targeting Phosphatases and Kinases: How to Checkmate Cancer |
Articolo in rivista |
Vai |
2021 |
A receptor-antibody hybrid hampering MET-driven metastatic spread |
Articolo in rivista |
Vai |
2021 |
HGF/MET Axis Induces Tumor Secretion of Tenascin-C and Promotes Stromal Rewiring in Pancreatic Cancer |
Articolo in rivista |
Vai |
2020 |
Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody |
Articolo in rivista |
Vai |
2019 |
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours |
Articolo in rivista |
Vai |
2018 |
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy |
Articolo in rivista |
Vai |
2018 |
MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk |
Review essay (rassegna critica) |
Vai |
2016 |
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody |
Articolo in rivista |
Vai |